The Irell & Manella Graduate School of Biological Sciences trains students to apply their talents and creativity toward advancing our knowledge of deadly diseases…and finding cures.
City of Hope has an enduring commitment to continuing medical education, sharing advances in cancer research and treatment with the healthcare community through conferences and symposia.
We provide an innovative series of educational programs for nurses, radiation therapists, pharmacists, cancer researchers and others.
City of Hope offers a range of valuable programs and training for postdoctoral trainees, medical professionals and our own staff.
City of Hope offers a distinctive setting for research, one in which scientists’ work is consistently applied to finding novel therapies for life-threatening diseases.
A team from City of Hope is working on a vaccine for congenital cytomegalovirus (CMV), symptoms of which can range from hearing and vision loss to intellectual disability to small head size to frequent seizures. More than half of adults over the age of 40 are infected with the virus.
Many people struggle with both diabetes and cancer at the same time — none of this is random or coincidental. Rather, it's clear that, from biology to risk factors to treatment options, cancer and diabetes are intimately related in many ways.
A cure for Type 1 diabetes (T1D) in six years is the new goal of City of Hope’s Diabetes and Metabolism Research Institute. With more than $50 million in private funding, the institute will be able to lead an innovative research effort that seeks to find a cure for T1D.
Diabetes affects over 422 million people worldwide according to the World Health Organization, but no two patients are alike. So in 2017 and beyond, treatments will increasingly make use of precision medicine to personalize treatment options. At City of Hope, researchers are combining the forces of a transformative gift with new resources to speed these treatments to patients.
At City of Hope, scientists are using a transformative gift to speed type 1 diabetes therapies to patients.